Vanbact I.V

Indications

• Surgical procedures
• Injection of medications
• Preparation of sterile pharmaceutical products
• Management of open wounds
• Use in controlled environments such as hospitals and laboratories

Dosage

Children: Refer to specific drug monographs for dosage information as sterile itself is not a pharmacological agent.

Adults: Refer to specific drug monographs for dosage information as sterile itself is not a pharmacological agent.

Mechanism of action

Sterility itself does not have a mechanism of action as it is a state of cleanliness and does not interact with biological systems. However, the methods used to achieve sterility, such as heat or chemical agents, act by denaturing proteins, disrupting cellular structures, or damaging nucleic acids in microorganisms, leading to their inactivation or destruction.

Pharmacodynamics

The pharmacodynamics of sterile techniques primarily involves the prevention of microbial infection and contamination when administering medications. By ensuring that products are sterile, the risk of adverse effects related to infections is minimized. The effectiveness of sterilization methods can be influenced by factors such as temperature, duration of exposure, and the type of microorganisms present.

Pharmacokinetics

As sterility does not pertain to a specific drug, pharmacokinetics is not applicable. However, the pharmacokinetics of a drug will depend on its formulation, route of administration, and the presence of preservatives or stabilizers that may be used alongside sterile preparations.

Pregnancy

Sterile preparations are generally considered safe during pregnancy as they are used to provide hydration, nutrition, or medications in a controlled manner, but specific formulations should be assessed individually.

Breast-feeding

Sterile solutions used for hydration or nutritional support are typically safe during breastfeeding, but any specific additives or medications within the solutions should be evaluated for safety.

Storage

Sterile solutions should be stored in a cool, dry place, protected from light, and should be used before the expiration date. Once opened, they may have specific storage requirements based on the formulation.

Formulations

• Sterile saline solution
• Sterile water for injection
• Sterile dextrose solution
• Sterile electrolyte solutions

Indications

• Complicated skin and soft tissue infections
• Bone infections
• Joint infections
• Community-acquired pneumonia
• Hospital-acquired pneumonia, including ventilator-associated pneumonia
• Infective endocarditis
• Acute bacterial meningitis
• Bacteraemia
• Surgical prophylaxis for patients at high risk of bacterial endocarditis

Mechanism of action

Vancomycin exerts its bactericidal action by inhibiting cell wall biosynthesis. It specifically binds to the terminal D-alanyl-D-alanine residues of the peptidoglycan precursors, preventing their incorporation into the peptidoglycan matrix, which is vital for the structural integrity of Gram-positive bacteria. This leads to cell lysis and death. Additionally, vancomycin alters bacterial cell membrane permeability and affects RNA synthesis, contributing to its antimicrobial effects.

Pharmacodynamics

As a nonribosomal peptide antibiotic, vancomycin is often considered a drug of last resort and is used when other treatments have failed. It demonstrates activity against several significant pathogens, including Listeria monocytogenes, Streptococcus pneumoniae (including penicillin-resistant strains), and various enterococci. Vancomycin can synergistically enhance the effects of aminoglycosides against certain strains, leading to improved clinical outcomes in specific infections.

Pharmacokinetics

Vancomycin is administered intravenously or intramuscularly, with its pharmacokinetics influenced by renal function. The drug is distributed widely in body tissues and fluids, with a volume of distribution of approximately 0.4 to 1 L/kg. It is primarily eliminated via the kidneys, necessitating dosage adjustments in patients with renal impairment. Trough concentrations should be monitored to ensure efficacy while preventing toxicity, especially during prolonged therapy.

Contra-indications

• Previous hearing loss
• Hypersensitivity to vancomycin or any component of the formulation

Adverse effects

• Nephrotoxicity
• Ototoxicity
• Red man syndrome
• Thrombophlebitis
• Hypersensitivity reactions
• Skin rash

Interactions

• Increased risk of nephrotoxicity when used with other nephrotoxic drugs (e.g., aminoglycosides, nonsteroidal anti-inflammatory drugs)
• Potential interactions with muscle relaxants and anesthetics

Precautions

• Monitor renal function and auditory function during prolonged treatment
• Use with caution in patients with renal impairment
• Assess for potential allergic reactions prior to administration

Pregnancy

Vancomycin is classified as category B. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Vancomycin is excreted in breast milk. Caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place. Protect from light. Do not freeze.

Formulations

• Solution for injection
• Powder and solvent for solution for injection

Mechanism of action

The bactericidal action of vancomycin results primarily from inhibition of cell-wall biosynthesis. Specifically, vancomycin prevents incorporation of N-acetylmuramic acid (NAM)- and N-acetylglucosamine (NAG)-peptide subunits from being incorporated into the peptidoglycan matrix, which forms the major structural component of Gram-positive cell walls. Vancomycin forms hydrogen bonds with the terminal D-alanyl-D-alanine moieties of the NAM/NAG-peptides, preventing the incorporation of the NAM/NAG-peptide subunits into the peptidoglycan matrix. In addition, vancomycin alters bacterial-cell-membrane permeability and RNA synthesis. There is no cross-resistance between vancomycin and other antibiotics. Vancomycin is not active in vitro against gram-negative bacilli, mycobacteria, or fungi. Vancomycin is bactericidal and appears to bind to the bacterial cell wall causing blockage of glycopeptide polymerization. This effect, which occurs at a site different from that affected by the penicillins, produces immediate inhibition of cell wall synthesis and secondary damage to the cytoplasmic membrane. Magnesium, manganese, calcium, and ferrous ions reduce the degree of adsorption of vancomycin to the cell wall, but the in vivo importance of this interaction is unknown. The bactericidal action of vancomycin results primarily from inhibition of cell-wall biosynthesis. In addition, vancomycin alters bacterial-cell-membrane permeability and RNA synthesis.

Pharmacodynamics

Vancomycin is a branched tricyclic glycosylated nonribosomal peptide often reserved as the "drug of last resort", used only after treatment with other antibiotics has failed. Vancomycin has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections: <i>Listeria monocytogenes</i>, <i>Streptococcus pyogenes</i>, <i>Streptococcus pneumoniae</i> (including penicillin-resistant strains), <i>Streptococcus agalactiae</i>, <i>Actinomyces</i> species, and <i>Lactobacillus</i> species. The combination of vancomycin and an aminoglycoside acts synergistically in vitro against many strains of Staphylococcus aureus, Streptococcus bovis, enterococci, and the viridans group streptococci.